Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Soluble guanylate cyclase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Soluble guanylate cyclase. Displaying page 1 of 1.
    EudraCT Number: 2016-001412-38 Sponsor Protocol Number: CQCC374X2201 Start Date*: 2017-07-27
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, parallel-group, placebo-controlled subject and investigator blinded study to assess the safety, tolerability, pharmacokinetics and efficacy of QCC374 in the treatment of pulmonary art...
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001525-28 Sponsor Protocol Number: ICL-INONAC1 Start Date*: 2006-03-24
    Sponsor Name:Imperial College London
    Full Title: INFLUENCE OF THE ANTIOXIDANT N-ACETYLCYSTEINE ON INHALED NITRIC OXIDE INDUCED PULMONARY RESPONSES FOLLOWING HUMAN LUNG ISCHAEMIA-REPERFUSION INJURY
    Medical condition: heart-lung transplantation
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004815-29 Sponsor Protocol Number: ULA03 Start Date*: 2021-08-04
    Sponsor Name:Cardiorentis AG
    Full Title: Open-label, dose escalation study of ularitide for the investigation of hemodynamic effects in patients with pulmonary arterial hypertension (UPAH)
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001187-33 Sponsor Protocol Number: APD811-301 Start Date*: 2019-02-12
    Sponsor Name:Arena Pharmaceuticals, Inc.
    Full Title: A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients
    Medical condition: pulmonary arterial hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077731 Pulmonary hypertension WHO functional class I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) SE (Prematurely Ended) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) BG (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) HR (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000671-25 Sponsor Protocol Number: 1242-001 Start Date*: 2016-09-30
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi- Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in S...
    Medical condition: Treatment of chronic heart failure with reduced ejection fraction (HFrEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) CZ (Completed) HU (Completed) ES (Completed) FR (Completed) GB (Completed) DK (Completed) NL (Completed) FI (Completed) PL (Completed) BE (Completed) GR (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002817-21 Sponsor Protocol Number: AC-065A310 Start Date*: Information not available in EudraCT
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Event-Driven, Group-Sequential Study with Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as ...
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) PL (Trial now transitioned) SE (Trial now transitioned) DE (Ongoing) ES (Ongoing) HU (Trial now transitioned) BE (Trial now transitioned) BG (Trial now transitioned) PT (Trial now transitioned) LT (Trial now transitioned) FI (Trial now transitioned) IT (Trial now transitioned) IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002414-40 Sponsor Protocol Number: CXA-10-2302 Start Date*: 2019-12-17
    Sponsor Name:Complexa Inc.
    Full Title: A Phase 2, Multi-Center, Open-Label Study to Evaluate Long-term Safety and Efficacy of CXA-10 in Subjects with Pulmonary Arterial Hypertension on Stable Background Therapy: Extension to Study CXA-1...
    Medical condition: Pulmonary Arterial Hypertension (PAH).
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001899-11 Sponsor Protocol Number: C1701-202 Start Date*: 2019-11-07
    Sponsor Name:Cyclerion Therapeutics, Inc.
    Full Title: A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients with Stable Sickle Cell Disease
    Medical condition: Stable Sickle Cell Disease (SCD)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-002400-20 Sponsor Protocol Number: 81866 Start Date*: 2023-02-28
    Sponsor Name:Amsterdam UMC, location VUmc
    Full Title: Feasibility of empagliflozin as treatment for idiopathic pulmonary arterial hypertension
    Medical condition: Idiopathic Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077731 Pulmonary hypertension WHO functional class I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004783-22 Sponsor Protocol Number: 67896049PAH4005 Start Date*: 2020-12-03
    Sponsor Name:ACTELION Pharmaceuticals Ltd.
    Full Title: A PRospective, Multicenter, Single-arm, Open label, Phase 4 Study of the Effects of Selexipag on RighT Ventricular RemOdeling in Pulmonary Arterial Hypertension Assessed by Cardiac Magnetic REsonan...
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) GB (GB - no longer in EU/EEA) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003309-88 Sponsor Protocol Number: ROR-PH-302 Start Date*: 2020-06-02
    Sponsor Name:United Therapeutics Corporation
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by Cardiopulmonary Exercise Testing in Subjects with World He...
    Medical condition: pulmonary arterial hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077731 Pulmonary hypertension WHO functional class I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) AT (Prematurely Ended) DE (Prematurely Ended) ES (Ongoing) PL (Prematurely Ended) BE (Completed) IT (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002287-11 Sponsor Protocol Number: BAY1021189/15371 Start Date*: 2013-12-12
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized parallel-group, placebo-controlled, double-blind, multi-center dose finding phase II trial exploring the pharmacodynamic effects, safety and tolerability, and pharmacokinetics of four ...
    Medical condition: Heart failure
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed) AT (Completed) BE (Completed) SE (Completed) DK (Completed) DE (Completed) ES (Completed) NL (Completed) HU (Completed) BG (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2013-002288-25 Sponsor Protocol Number: BAY1021189/15829 Start Date*: 2013-12-12
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized parallel-group, placebo-controlled, double-blind, multi-center dose finding phase II trial exploring the pharmacodynamic effects, safety and tolerability, and pharmacokinetics of four ...
    Medical condition: Heart failure
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed) AT (Completed) BE (Completed) SE (Completed) DK (Completed) NL (Completed) ES (Completed) HU (Completed) BG (Completed) PT (Completed) GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 06:20:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA